Minerva Neurosciences Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of product candidates for central nervous system diseases. Its lead product candidate, roluperidone, targets negative symptoms in patients with schizophrenia, such as blunted affect, alogia, avolition, anhedonia, and asociality, addressing a significant unmet medical need where no specific treatments are approved. The company also holds exclusive rights to MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein, for Parkinson’s disease and other neurodegenerative disorders. Minerva Neurosciences Inc. emphasizes innovative clinical trial designs with endpoints linked to patient benefits, recruiting suitable participants for its therapies. Operating in the biotechnology sector within healthcare, it concentrates on research, clinical development, and regulatory interactions for chronic, disabling neurologic and psychiatric conditions. Founded in 2007 and headquartered in Burlington, Massachusetts, the company advances its pipeline to enhance therapeutic options in CNS disorders.